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Uterine carcinosarcoma associated with pelvic radiotherapy for sacral
chordoma: A case report
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Accepted 28 December 2010AbstractObjective: Postirradiation sarcoma of the female genital tract is rare, but a recognized event. Most reported cases have been associated with
history of radiotherapy for various gynecologic conditions, particularly cancer of the uterine cervix and abnormal uterine bleeding. The
occurrence of uterine sarcoma secondary to radiotherapy for a non-gynecologic tumor and, furthermore, this condition being simultaneous with
the recurrence of primary tumor is unique.
Case Report: A 67-year-old woman presented with a uterine mass which was diagnosed as a sarcoma by endometrial curettage and history of
pelvic radiotherapy 23 years previously for sacral chordoma. Surgical staging procedure for uterine malignancy was performed. The final
pathologic diagnosis was carcinosarcoma of the uterus.
Conclusion: In uterine masses seen in patients with history of irradiation to the pelvic field, the probability of uterine sarcomas should always be
kept in mind. These tumors may occur simultaneously with recurrence of primary tumor previously treated by adjuvant radiation therapy.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Carcinosarcoma of the uterus, also referred to as malignant
mixed Mu¨llerian tumor, is a rare neoplasm composed of
epithelial and mesenchymal malignant elements. These tumors
accounting for 40e50% of all uterine sarcomas usually occur
in postmenopausal women with a peak incidence at the ages of
60e70 years [1,2].
Previous pelvic irradiation is a recognized predisposing
factor for uterine carcinosarcoma which has been estimated to
occur in approximately 15% of cases [3]. Despite this defined
relationship, no specific clinical or histopathological features
distinguish between radiation-associated and de novo uterine
sarcomas.* Corresponding author. Department of Obstetrics and Gynecology, Ankara
University School of Medicine, 06100 Ankara, Turkey.
E-mail address: korhankahraman@hotmail.com (K. Kahraman).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2012.01.018Chordoma is a rare, slowly growing, locally aggressive,
malignant bone tumor that originates from notochordal
remnants and occurs exclusively in the axial skeleton. The
sacrum is the most common location of the chordomas [4].
Herein we present a unique case of uterine carcinosarcoma
and recurrent sacral chordoma occurring simultaneously in
a 67-year-old woman who had a history of pelvic irradiation
for sacral chordoma 23 years previously. The clinical, radio-
graphic, and pathologic features of this case are discussed.
Case report
A 67-year-old, multiparous woman was referred to our
clinic with the diagnosis of uterine sarcoma in November
2009. Eleven days before she was referred, an endometrial
curettage was performed because of postmenopausal uterine
bleeding and revealed a sarcomatous malignancy at another
center, but differential diagnosis between high-grade leio-
myosarcoma and carcinosarcoma could not be done. She wascs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
90 K. Kahraman et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 89e92operated because of sacral chordoma in 1986 with follow-up
radiation therapy [posterior and anterior pelvic fields of
13 17 cm delivering a dose of 5000 rad (50 Gy) in 25 frac-
tions between March and May 1986]. In addition, repeated
surgeries were performed for the recurrence of sacral chor-
doma in 1989, 1999, and 2002. She had been menopausal
since the age of 44 years and had never used hormone
replacement therapy. She had no history of tamoxifen use. Her
medical history was significant for diabetes mellitus and
hypertension. In April 2009, a magnetic resonance imaging
(MRI) scan was performed at another hospital because of
a painful swelling in the lumbo-sacral region, and showed
a mass indicative of sacral chordoma recurrence (Fig. 1A, B).
The same MRI scan also showed a uterine mass measuring
62 42 38 mm that completely filled the uterine cavity
(Fig. 1A, B). Despite these MRI findings suggesting a uterine
tumor, further diagnostic interventions to demonstrate or rule
out uterine malignancy had not been performed at the same
center. With a possible diagnosis of recurrent sacral chordoma,
she had been treated with radiotherapy according to the
following schedule: a total of 2600 cGy (26 Gy) in 13 frac-
tions between April and May 2009. Follow-up MRIs did not
show a significant reduction in the size of the sacral mass.
Tumor markers were normal except mildly elevated serum
cancer antigen 125: 71.6 U/mL (reference range <35 U/mL).
A chest radiograph and computerized tomographic scan of
thorax and upper abdomen were negative for metastatic
disease.
With a diagnosis of uterine sarcoma, exploratory laparotomy
was performed at our clinic. Laparotomy revealed an enlarged
uterus totally with a mass probably representing sarcoma. The
uterine tumor invaded the bladder and the uterus was adherent
to the recto-sigmoid colon, omentum, and peripheral structures.
Minimal serous-hemorrhagic ascites was observed. Both
ovaries were atrophic. Other pelvic and abdominal structures
and peritoneal surfaces were all grossly normal. A stagingFig. 1. (A) T1-weighted sagittal image; a hypointense recurrent sacral chordoma (bl
of the uterus (white arrows). (B) T2-weighted sagittal image; the relatively hyperin
mass denote hemorrhage. The sacral chordoma (black arrow) is also seen as a relat
terminale.procedure was performed including a peritoneal washing for
cytological evaluation, total hysterectomy, bilateral salpingo-
oophorectomy, para-aortic lymph node dissection, infracolic
omentectomy, multiple peritoneal biopsies, and partial resection
of the bladder invaded by the tumor. Pelvic lymphadenectomy
was not performed because of technical difficulties resulting
from the excessive fibrosis at the pelvic lymph node regions
secondary to previous radiotherapy.
Macroscopic evaluation showed a polypoid mass filling the
uterine cavity, 7 cm long in diameter, with a hemorrhagic,
necrotic, fleshy cut surface. Histopathological evaluation of the
uterine mass revealed a neoplasm composed of an admixture
of malignant epithelial and mesenchymal components. The
epithelial component was endometrioid type adenocarcinoma
(Fig. 2A, B) and the sarcomatous areas were poorly differen-
tiated with highly atypical spindle cells and numerous atypical
mitotic figures (Fig. 2C). Areas of osteosarcoma were detected
as heterologous element (Fig. 2D). Vimentin expression was
strong and extensive in sarcomatous areas and focally in
epithelial component (Fig. 3A). Epithelial component showed
diffuse and strong cytokeratin expression immunohistochemi-
cally (Fig. 3B). Scattered smooth muscle actin (SMA)
expression was detected in a few cells of sarcomatous areas
indicating poorly differentiated leiomyosarcoma (Fig. 3C).
There was extensive myometrial invasion exceeding the inner
half. Bilateral paraovarian tissues and urinary bladder were
infiltrated. Lymph node involvement was confined to only one
(1/12) para-aortic lymph node. Omentum and both ovaries
showed no evidence of malignancy. The cytology of peritoneal
fluid was negative for malignant cells. Therefore, the final
diagnosis was a FIGO (Federation Internationale de Gyneco-
logie et d’Obstetrique) stage IVA uterine carcinosarcoma. She
recovered uneventfully and was discharged on the 13th post-
operative day in a stable condition. She received adjuvant
chemotherapy consisting of six cycles of paclitaxel (80 mg/m2)
and carboplatin (2 AUC). The first three cycles were given atack arrow) and a heterogeneous hypointense mass filling the endometrial cavity
tense uterine mass (white arrows). Hypointense areas within the endocavitary
ively hyperintense mass partially filling the spinal canal and abutting the filum
Fig. 2. Histological and immunohistochemical findings. (A, B) Glands lined by atypical pseudostratified columnar epithelium dispersed in sarcomatous areas
(H&E, 20, 20). (C) Poorly differentiated sarcomatous areas with marked nuclear atypia and numerous atypical mitotic figures (H&E, 20). (D) Osteosarcoma
as heterologous sarcomatous element with highly atypical spindle cells in an osteoid matrix (H&E, 20).
91K. Kahraman et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 89e92weekly intervals. There was a 2-week interval between the
third and fourth cycle, and the last three cycles were again
given weekly. Currently, at the 9th postoperative month, the
chemotherapy courses were completed and the patient was well
and disease-free in terms of uterine sarcoma.
Discussion
Postirradiation sarcoma of the female genital tract is rare,
but a significant long-term complication of pelvic radiotherapy.
The uterus is the most common site of irradiation-associated
sarcoma in the genital tract. These uterine sarcomas have
been mostly reported in patients treated with radiotherapy forFig. 3. (A) Diffuse vimentin expression in sarcomatous areas and focally in epithelia
(C) Scattered expression in a few cells of sarcomatous areas with SMA (40).malignancies of the uterine cervix, and for benign conditions
such as menorrhagia in early reports [5,6], but to the best of our
knowledge, a case of uterine sarcoma after radiation therapy
for sacral chordoma has not previously been reported in the
English literature.
To consider a sarcoma to be irradiation-associated, some
criteria must be met, including: (i) the development of
sarcoma must be within a previously irradiated field; (ii)
patients should have received a significant amount of radia-
tion; (iii) a latency period of several years (at least 3e5 years)
must elapse between the time of radiation and the develop-
ment of the sarcoma; (iv) the diagnosis of the sarcoma must be
histologically proven; and (v) the secondary sarcoma shouldl component (20). (B) Cytokeratin expression of epithelial component (20).
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present case satisfies all the above criteria. In the published
cases of uterine sarcoma seen in patients with history of
irradiation to the pelvic field, the interval between the time of
irradiation and the diagnosis of uterine sarcoma varies
between 3 and 30 years, with the total radiation doses ranging
from 2400 to 8000 cGy, and the most common type of
secondary uterine sarcoma is the carcinosarcoma [5,6]. In the
present patient, considering that the tumor arose within the
irradiation field after a long latency period (23 years), a diag-
nosis of irradiation-associated sarcoma was made. By contrast,
there are no specific clinical or histopathological features
distinguishing between irradiation-associated and irradiation
not associated uterine sarcomas. Therefore, it cannot be
completely ruled out that the occurrence of uterine carcino-
sarcoma in this patient may be de novo.
Comprehensive surgical staging is the primary treatment
modality of uterine carcinosarcomas. Although there is little
evidence to support the benefit of adjuvant treatment in
advanced disease, the use of adjuvant chemotherapy and/or
radiotherapy is generally recommended. Adjuvant radio-
therapy for uterine carcinosarcoma has not been evaluated
adequately, but a study has demonstrated the advantage of
radiotherapy for local control in advanced disease [2].
However, considering the possibility of significant adverse
effects, pelvic radiotherapy was not performed as the present
patient had been exposed to prior pelvic radiotherapy twice,
and she received only chemotherapy as an adjuvant treatment.
Surgical stage and depth of myometrial invasion have been
suggested as very important prognostic factors. At presenta-
tion, extrauterine extend is found in up to one-third of patients
with uterine carcinosarcomas and their survival is very poor
[1,2]. A history of pelvic irradiation is more frequently asso-
ciated with extrauterine disease at clinical presentation. It has
been suggested that the reason extrauterine disease is more
frequent in patients that were exposed to pelvic irradiation is
due to cervical stenosis, which develops as a result of past
radiotherapy, hindering uterine bleeding, which is the most
common presenting symptom of uterine sarcoma; thus, if the
disease presents itself with symptoms other than uterine
bleeding it is at a more advanced stage [8]. This is supported
by a study, comparing spontaneous uterine carcinosarcoma
with irradiation-associated sarcoma, stating that uterine
bleeding was the most common presenting symptom of
spontaneous carcinosarcoma, whereas the most common pre-
senting symptom of irradiation-associated uterine carcinosar-
coma is abdominal distension and pain [5]. However, proof of
this theory requires further clinicopathologic studies evalu-
ating the possible fibrosis and stenosis of the cervical canal
histopathologically. In the present case, we re-evaluated the
patient’s previous MRI scans, when she applied to our clinicwith the results of her probe curettage that was performed at
another medical facility, as she presented with postmenopausal
bleeding 5 months after her first MRI was taken in April 2009
and the uterine mass was diagnosed, for which no previous
intervention was performed. It is difficult to interpret the
relation of this delay in diagnosis and the effect of radio-
therapy as re-irradiation for recurrent sacral chordoma on the
prognosis of uterine carcinosarcoma. In addition, although the
post-radiotherapy MRI revealed no significant reduction in the
size of uterine mass, the lesion had changes in accordance with
necrosis and bleeding. This necrosis and bleeding, developing
after radiotherapy, may hinder a further delay in diagnosis by
leading to uterine bleeding; however; it is difficult to explain
why this uterine bleeding developed 5 months later, instead of
occurring relatively earlier.
In two large studies on post-irradiation uterine sarcoma [5,6],
most patients were exposed to radiation, performed as a primary
treatment modality for cervical cancer. Furthermore, in these
studies, patients that were exposed to radiation for abnormal
uterine bleeding were second in rank; however, radiotherapy for
the treatment of abnormal uterine bleeding does not currently
include this method. None of these studies included patients
with non-gynecologic radiotherapy indications.
In conclusion, the probability of uterine sarcomas should
always be kept in mind in a uterine mass seen in a patient with
a history of pelvic field radiotherapy. Furthermore, another
point to be considered is that irradiation-associated neoplasm
and recurrence of primary tumor previously treated by adju-
vant radiation therapy may occur simultaneously.References
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